Novartis, CH0012005267

Novartis stock gets USD 156 target as FDA approves Rhapsido

Published on 10/08/2026 at 11:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Rhapsido trial response reached 29.30 percent versus 14.00 percent placebo. Novartis stock was at EUR 126.95 on October 8, 2026.

Draufsicht auf Tabletten, Blisterpacks, Beipackzettel und Stethoskop auf weißem Untergrund — Novartis AG CH0012005267 – Flatlay mit generischen Tabletten, Blister, Beipackzettel und Stethoskop auf Weiß, Illustration mit AI erstellt.

Novartis stock was at EUR 126.95 at Lang & Schwarz on October 8, 2026 at 11:08 a.m. CEST as the company advanced Rhapsido through a fresh US regulatory approval. On October 7, 2026, Novartis announced that the FDA approved Rhapsido, or remibrutinib, as the first treatment for adults with symptomatic dermographism inadequately controlled by H1 antihistamines.

Rhapsido expands its indication

The approval extends Rhapsido beyond chronic spontaneous urticaria and gives the medicine approved uses across the two most common forms of chronic hives. Novartis said the Phase III RemIND trial recorded complete hive resolution at Week 12 for 29.30 percent of patients receiving Rhapsido, compared with 14.00 percent receiving placebo.

The response gap was more than a clinical footnote. It gives Novartis a quantified regulatory and commercial argument for expanding remibrutinib across immune-mediated diseases, while the company said responses appeared as early as Week 2. The release also reported a consistent safety profile through Week 24, with nasal congestion, sore throat, headache, nausea and abdominal pain among the listed adverse events.

Analysts weigh pipeline execution

Pipeline delivery remains central to the valuation debate. Markets Insider reported on October 6, 2026 that Morgan Stanley cut its Novartis price target from USD 170.00 to USD 156.00 and retained an Overweight rating. The target change puts greater weight on execution across launches and clinical programs than on a single approval.

MarketBeat reported on October 7, 2026 that 20 analysts covered Novartis, with 12 Hold, six Buy and two Sell ratings and an average 12-month target of USD 145.60. That split shows why the Rhapsido approval matters: the pipeline can add growth, but investors continue to distinguish regulatory progress from broader earnings delivery.

Q3 results set the next test

Novartis reported second-quarter 2026 revenue of USD 14.95 billion, according to MarketBeat. The company calendar lists third-quarter 2026 financial results for October 27, 2026, giving investors a scheduled checkpoint for sales momentum and launch contribution, per the Novartis investor calendar.

Novartis stock was trading at EUR 126.95 at Lang & Schwarz on October 8, 2026 at 11:08 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Novartis stock.